## AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims:

 (Currently Amended) A sulfonamide compound according to formula I

$$Ar^{1}$$
  $N$   $(CH_{2})_{n}$   $Ar^{2}$   $SO_{2}$   $Y$ 

with its geometrical isomers, in an optically active form as enantiomers, diastereomers, as well as in the form of racemates, as well as pharmaceutically acceptable salts thereof, wherein

Ι

Ar¹ is selected from the group consisting of phenyl, thienyl, furanyl, pyridyl, and optionally substituted by substituted or unsubstituted  $C_1$ - $C_6$  alkyl, substituted or unsubstituted  $C_1$ - $C_6$  alkoxy, substituted or unsubstituted  $C_2$ - $C_6$  alkenyl, substituted or unsubstituted  $C_2$ - $C_6$  alkenyl, amino, acylamino, aminocarbonyl,  $C_1$ - $C_6$  alkoxycarbonyl, aryl, carboxyl, cyano, halo, hydroxy, nitro, sulfonyl, sulfoxy, acyloxy,  $C_1$ - $C_6$  thioalkoxy;

 ${\mbox{Ar}}^2$  is selected from the group consisting of thienyl, furanyl, and pyridyl;

X is O or S;

 $$\rm R^1$$  is hydrogen or a  $\rm C_1\text{--}C_6\text{--}alkyl$  group, or  $\rm R^1$  forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with  $\rm Ar^1;$ 

n is an integer from 0 to 5:

Y is a piperidino group of the formula



#### wherein

with  $R^3$  and  $R^{3'}$  being substituents independently selected from the group consisting of H, substituted or unsubstituted  $C_2$ - $C_6$ -alkyl, substituted or unsubstituted  $C_2$ - $C_6$ -alkenyl, substituted or unsubstituted aryl, substituted or

unsubstituted heteroaryl, substituted or unsubstituted aryl- $C_1$ - $C_6$ -alkyl, and substituted or unsubstituted heteroaryl- $C_1$ - $C_6$ -alkyl;

said aryl or heteroaryl groups being optionally substituted  $C_1$ - $C_6$ -alkyl,  $C_1$ - $C_6$ -alkoxy,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl, amino, acylamino, aminocarbonyl,  $C_1$ - $C_6$ -alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfonyl, sulfoxy or  $C_1$ - $C_6$ -thioalkoxy; and

 $R^6$  is selected from the group consisting of hydrogen, substituted or unsubstituted  $C_1$ - $C_6$ -alkyl, substituted or unsubstituted  $C_1$ - $C_6$ -alkoxy, OH, halogen, nitro, cyano, sulfonyl, and oxo (=0); and

n' is an integer from 0 to 4;

with the proviso that if  $Ar^1$  is 4-chlorophenyl, then X is O,  $R^1$  is H,  $Ar^2$  is thienyl, and Y is not para-substituted by 2-hydroxyethyl;

with the further provise that if Ar is phenyl, then

X is O, R\* is H, Ar\* is thicmyl, and Y is not substituted in

its B-position by a benzo [5,6] cyclohepta [1,2b] pyridine or

a-benzo [5,6] cyclohept [3,4] ene [1,2b] pyridine;

with the final provise that if X is exygen, then Y shall not be substituted by a group (C=0)N(R,R') at the  $\alpha$ -position of the sulfonamide nitrogen in which R and R' are

independently-chosen\_from-hydrogen, C<sub>1</sub>-C<sub>5</sub>-alkyl, -aryl, heteroaryl, C<sub>4</sub>-C<sub>5</sub>-alkyl aryl or C<sub>2</sub>-C<sub>6</sub>-alkyl heteroaryl,

wherein the term "substituted" means that the group that is substituted is substituted with from its 5 substituents, said substituents being a group selected from the group consisting of  $C_1\text{-}C_6$  alkyl;  $C_1\text{-}C_6$  alkyl aryl;  $C_1\text{-}C_6$  alkyl heteroaryl;  $C_2\text{-}C_6$  alkenyl;  $C_2\text{-}C_6$  alkynyl; primary, secondary or tertiary amino groups; quaternary ammonium groups; acyl; acyloxy; acylamino; aminocarbonyl; alkoxycarbonyl; aryl; heteroaryl; carboxyl; cyano; halogen; hydroxyl; mercapto; nitro; sulfoxy; sulfonyl; alkoxy, thioalkoxy; and trihalomethyl.

 (Currently Amended) A composition comprising a sulfonamide compound according to formula I

with its geometrical isomers, in an optically active form as enantiomers, <u>diastereomers</u> diastereoisomers, as well as in the form of racemates, as well as pharmaceutically acceptable salts thereof, wherein

X is O or S;

Ar<sup>1</sup> and Ar<sup>2</sup> are a substituted or unsubstituted aryl or heteroaryl group-with the provise that Ar<sup>2</sup> is neither 1,3-phenylene or 1,4-phenylene and Ar<sup>3</sup> is not phenylene or quinazoline that is substituted by nitro, hydroxyl, or 3,4-dichlorophenyl amine;

 $R^1$  is hydrogen or a  $C_1\text{--}C_6\text{--alkyl}$  group, or  $R^1$  forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with  $Ar^1;$ 

n is an integer from 0 to 5;

Y is a piperidino group of the formula



wherein

 $L^1$  and  $L^2$  are independently selected from the group consisting of H, substituted or unsubstituted  $C_1$ - $C_6$ -alkyl, substituted or unsubstituted  $C_2$ - $C_6$ -alkenyl, substituted or unsubstituted  $C_2$ - $C_6$ -alkynyl, and substituted or unsubstituted cyclic  $C_4$ - $C_8$ -alkyl optionally containing 1-3 heteroatoms and optionally fused with aryl or heteroaryl; or  $L^1$  and  $L^2$  are independently selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, aryl- $C_1$ - $C_6$ -alkyl, heteroaryl- $C_1$ - $C_6$ -

alky1,  $-C(0) - OR^3$ ,  $-C(0) - R^3$ ,  $-C(0) - NR^2 R^3$ ,  $-NR^2 R^3$ ,  $-NR^3 C(0) R^3$ ,  $-NR^3 C(0) NR^3 R^3$ ,  $-(SO) R^3$ ,  $-(SO) R^3$ ,  $-NHSO_2 R^3$ , and  $-SO_2 NR^3 R^3$ ,

with  $R^3$  and  $R^{2'}$  being substituents independently selected from the group consisting of H, substituted or unsubstituted  $C_1$ - $C_6$ -alkyl, substituted or unsubstituted  $C_2$ - $C_6$ -alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted aryl- $C_1$ - $C_6$ -alkyl, and substituted or unsubstituted heteroaryl- $C_1$ - $C_6$ -alkyl,

said aryl or heteroaryl groups being optionally substituted  $C_1$ - $C_6$ -alkyl,  $C_1$ - $C_6$ -alkoxy,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl, amino, acylamino, aminocarbonyl,  $C_1$ - $C_6$ -alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfonyl, sulfoxy, or  $C_1$ - $C_6$ -thioalkoxy; and

 $R^6$  is selected from the group consisting of hydrogen, substituted or unsubstituted  $C_1$ - $C_6$ -alkyl, substituted or unsubstituted  $C_1$ - $C_6$ -alkoxy, OH, halogen, nitro, cyano, sulfonyl, and oxo (=0); and

n' is an integer from 0 to 4;

with the proviso that if Y is substituted at the ß-position of the piperidino- nitrogen by a benzo[5, 6]cyclohepta[1, 2b]pyridine, or a benzo[5, 6]cyclohept [3,4] ene [1, 2b]pyridine, while Ar<sup>2</sup> is thienyl, X is oxygen, R<sup>1</sup> is hydrogen and n is 1, Ar<sup>2</sup> shall not be a phenyl group;

Appln. No. 10/070,954 Amdt. dated March 3, 2010

Reply to Office Action of November 3, 2009

and a pharmaceutically acceptable carrier.

with the final provise that if X is exygen, Y shall not be substituted by a group (C=0)N(R,R') at the  $\alpha$  position of the sulfonamide nitrogen in which R and R' are independently chosen from hydrogen,  $C_k$   $C_6$ -alkyl, aryl, heteroaryl,  $C_k$   $C_6$ -alkyl aryl or  $C_k$   $C_6$ -alkyl heteroaryl.

### 3-4. (Cancelled)

- 5. (Previously Presented) A sulfonamide compound according to claim 1, wherein Ar¹ is selected from the group consisting of phenyl, thienyl, furyl, pyridyl, and optionally substituted by  $C_1$ - $C_6$ -alkyl,  $C_1$ - $C_6$ -alkoxy,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl, amino, acylamino, aminocarbonyl,  $C_1$ - $C_6$ -alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfonyl and  $C_1$ - $C_6$ -thioalkoxy.
- 6. (Previously Presented) A sulfonamide compound according to claim 5, wherein Ar<sup>1</sup> is an unsubstituted or substituted phenyl.
- 7. (Previously Presented) A sulfonamide compound according to claim 5, wherein  ${\rm Ar}^2$  is thienyl or furanyl group.

8. (Previously Presented) A sulfonamide compound according to claim 1, wherein Ar¹ is selected from the group consisting of a 4-chlorophenyl, nitrophenyl, hydroxyphenyl, alkoxy phenyl, pyridyl, 3,4,-dihydroxyphenyl, and X is O, R¹ is hydrogen, n is 1, Ar² is thienyl or furanyl.

(Currently Amended) A sulfonamide compound according to claim 8, wherein Y is



 $\{R^6\}_{-n^4}$  is selected from the group consisting of hydrogen, substituted or unsubstituted  $C_1.C_6$  alkyl, substituted or unsubstituted  $C_1-C_6$  alkoxy, OH, halogen, nitro, cyano, sulfonyl, and oxo; n' is an integer of from 0 to 4; and

wherein  $L^1$  and  $L^2$  are independently selected from each other from the group consisting of H, substituted or unsubstituted  $C_1$ - $C_6$ - alkyl, substituted or unsubstituted  $C_2$ - $C_6$  alkenyl; or  $L^1$  and  $L^2$  are independently selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted or unsubstituted cyclic  $C_4$ - $C_8$  alkyl optionally containing 1-3 heteroatoms and optionally fused with aryl or heteroaryl, aryl- $C_1$ - $C_4$  alkyl,

heteroary1- $C_1$ - $C_4$  alky1, -C(0)-OR<sup>3</sup>, -C(0)-R<sup>3</sup>, -C(0)-NR<sup>3</sup>'R<sup>3</sup>, -NR<sup>3</sup>'R<sup>3</sup>, -NR<sup>3</sup>'R<sup>3</sup>, -NR<sup>3</sup>'C(0)R<sup>3</sup>, -NR<sup>3</sup>'C(0)R<sup>3</sup>, -NR<sup>3</sup>'C(0)R<sup>3</sup>, -NR<sup>3</sup>'C(0)R<sup>3</sup>, -NR<sup>3</sup>'C(0)R<sup>3</sup>, -NR<sup>3</sup>'C(0)R<sup>3</sup>, and -SO<sub>2</sub>NR<sup>3</sup>R<sup>3</sup>':

with  $R^3$  and  $R^{3'}$  being substituents independently selected from the group consisting of H, substituted or unsubstituted  $C_1$ - $C_4$  alkyl, substituted or unsubstituted  $C_2$ - $C_6$  alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aryl- $C_1$ - $C_4$ -alkyl, substituted or unsubstituted heteroaryl- $C_1$ - $C_6$ -alkyl,

said aryl or heteroaryl groups being optionally substituted with a member selected from the group consisting of  $C_1$ - $C_6$ -alkyl,  $C_1$ - $C_6$ -alkoxy,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl, amino, acylamino, aminocarbonyl,  $C_1$ - $C_6$ -alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfonyl, sulfoxy and  $C_1$ - $C_6$ -thioalkoxy.

10. (Previously Presented) A sulfonamide compound according to claim 9, wherein  $R^6$  is H,  $L^2$  is H,  $L^1$  is a 5-membered cyclic group containing 3 heteroatoms or  $L^2$  is -C(O)- $R^3$ . or -NHR $^3$ :

wherein Y is



n' is an integer of from 0 to 4;

with  $\mathbb{R}^3$  being a substituent selected from the group comprising or consisting of  $C_1\text{-}C_4\text{-}alkyl$ , aryl, heteroaryl, aryl- $C_1\text{-}C_4\text{-}alkyl$  and heteroaryl- $C_1\text{-}C_6\text{-}alkyl$ ;

said aryl or heteroaryl groups being optionally substituted by halogen, hydroxy, nitro, or sulfonyl.

11. (Currently Amended) A sulfonamide compound according to claim 1, selected from the group consisting of:

4-chloro-N-{5-[4-(3-trifluoromethanesulfonyl-phenylamino)-piperidine-1-sulfonyl]-thiophen-2-ylmethyl}-

4-chloro-N-[(5-{[4-(4-fluorobenzoyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-({5-[(4-hydroxy-4-phenylpiperidin-1-

yl)sulfonyl]thien-2-yl}methyl)benzamide;

benzamide;

 $\label{eq:N-optimization} $$N-(\{5-[(4-benzoylpiperidin-1-yl)sulfonyl]thien-2-yl}$$ withyl)-4-chlorobenzamide;$ 

4-chloro-N-[(5-{[4-(2-oxo-2,3-dihydro-1H-

benzimidazol-1-yl)piperidin-1-yl]sulfonyl}thien-2yl)methyl]benzamide;

```
Appln. No. 10/070.954
Amdt. dated March 3, 2010
Reply to Office Action of November 3, 2009
          N-({5-[(4-benzylpiperidin-1-yl)sulfonyl]thien-2-
v1}methv1)-4-chlorobenzamide;
          4-chloro-N-[(5-{[4-(2,4-difluorobenzoyl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          tert-butyl 1-[(5-{[(4-
chlorobenzovl)amino|methyl|thien-2-yl)sulfonyl|piperidin 4-
vlcarbamate;
          4-chloro-N-{[5-(piperidin-1-ylsulfonyl)thien-2-
yl]methyl}benzamide;
          4-chloro-N-{[5-({3-hydroxy-4-[3-
(trifluoromethyl)phenyl]piperidin-1-yl}sulfonyl)thien-2-
vl]methvl}benzamide;
          4-chloro-N-({5-[(4-hydroxypiperidin-1-
yl)sulfonyl]thien-2-yl}methyl)benzamide;
          N-({5-[(4-benzyl-4-hydroxypiperidin-1-
yl)sulfonyl]thien-2-yl}methyl)-4-chlorobenzamide;
          N-{ [5-({4-[(2-tert-butvl-1H-indol-5-
yl)amino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}-4-
chlorobenzamide:
          4-chloro-N-{[5-({4-[(phenylacetyl)amino]piperidin-1-
```

 $\label{lem:decomposition} $$4$-chloro-N-{[5-({4-(qhenylacety1)amino]piperidin-1-y1}sulfony1)thien-2-y1]methy1}$ benzamide;$ 

N-[(5-{[4-(2H-1,2,3-benzotriazol-2-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

```
Appln. No. 10/070,954
Amdt. dated March 3, 2010
Reply to Office Action of November 3, 2009
```

```
4-chloro-N-[(5-{[4-(4-chlorobenzovl)piperidin-1-
vl|sulfonvl}thien-2-vl)methvl|benzamide;
          N-{ [5-({4-[benzyl (methyl) amino] piperidin-1-
yl}sulfonyl)thien-2-yl]methyl}-4-chlorobenzamide;
          4-chloro-N-{[5-({4-[3-(2,4-dichlorophenyl)-1H-
pyrazol-5-yl]piperidin-1-yl}sulfonyl)thien-2-
yl]methyl}benzamide;
          4-chloro-N-[(5-{[4-(5-thien-2-yl-1H-pyrazol-3-
vl)piperidin-1-vl]sulfonvl}thien-2-vl)methvl]benzamide;
          4-chloro-N-[(5-{[4-(2,3,4,5,6-
pentamethylbenzovl)piperidin-1-vllsulfonvl}thien-2-
yl) methyl] benzamide;
          4-chloro-N-{[5-({4-[5-(4-methoxyphenvl)-1H-pvrazol-
3-vl]piperidin-1-vl}sulfonvl)thien-2-vl]methvl}benzamide;
          N-({5-[(4-anilinopiperidin-1-vl)sulfonvl]thien-2-
y1}methyl)-4-chlorobenzamide;
          4-chloro-N-[(5-{[4-(2-phenylethyl)piperidin-1-
vl|sulfonvl}thien-2-vl)methvl|benzamide;
          N-[(5-{[4-(1H-1,2,3-benzotriazol-1-vl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;
          2-{1-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2-
vl)sulfonvl]piperidin-4-vl}-2H-1,2,3-benzotriazole-5-
carboxvlic acid;
```

- 13 -

methyl 1-{1-[(5-{[(4-

chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4vl}-1H-1.2.3-benzotriazole-5-carboxvlate:

methyl 1-{1-[(5-{[(4-

chlorobenzoy1)amino]methyl}thien-2-yl)sulfonyl]piperidin-4yl}-1H-1,2,3-benzotriazole-6-carboxylate;

methyl 2-{1-[(5-{[(4-

chlorobenzoy1) amino]methyl}thien-2-yl) sulfonyl]piperidin-4yl}-2H-1,2,3-benzotriazole-5-carboxylate;

4-chloro-N-[(5-{[4-(6-chloro-1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl)benzamide;

4-chloro-N-{[5-({4-[5-(trifluoromethyl)-1H-1,2,3-

benzotriazol-1-yl]piperidin-1-yl}sulfonyl)thien-2yl]methyl}benzamide;

N-[(5-{[4-(7-aza-1H-benzimidazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

1-{1-[(5-{[(4-chlorobenzoy1)amino]methyl}thien-2y1)sulfonyl]piperidin-4-y1}-1H-1,2,3-benzotriazole-5carboxylic acid;

1-{1-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-yl}-1H-1,2,3-benzotriazole-6-carboxylic acid;

 $\label{eq:N-constraint} $N-[(5-\{[4-(2-amino-9H-purin-9-y1)piperidin-1-y1]sulfonyl\}thien-2-y1)methyl]-4-chlorobenzamide;$ 

```
Appln. No. 10/070,954
Amdt. dated March 3, 2010
Reply to Office Action of November 3, 2009
```

```
4-chloro-N-[(5-{[4-(9H-purin-9-yl)piperidin-1-
vl]sulfonyl}thien-2-vl)methvl]benzamide;
          N-[(5-{[4-(6-amino-9H-purin-9-yl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;
          4-chloro-N-({5-[(4-{6-nitro-1H-benzimidazo]-1-
yl}piperidin-1-yl)sulfonyl]thien-2-yl}methyl)benzamide;
          4-chloro-N-({5-[(4-{5-nitro-1H-benzimidazol-1-
yl}piperidin-1-yl)sulfonyl]thien-2-yl}methyl)benzamide;
          4-chloro-N-[(5-{[4-(2H-1.2.3-triazol-2-v1)piperidin-
1-yl]sulfonyl}thien-2-yl)methyl]benzamide;
          N-[(5-{[4-(1H-benzimidazol-1-vl)piperidin-1-
vl|sulfonvl}thien-2-vl)methvl|-4-chlorobenzamide:
          4-chloro-N-{[5-({4-[3-propylanilino]piperidin-1-
yl sulfonyl) thien-2-yl] methyl benzamide;
          4-chloro-N-{[5-({4-[3-
(dimethylamino)anilino|piperidin-1-vl}sulfonvl)thien-2-
yl]methyl}benzamide;
          methyl 3-({1-[(5-{[(4-chlorobenzoyl)amino]-
methyl }thien-2-yl) sulfonyl]piperidin-4-yl }amino) -benzoate;
          4-chloro-N-{[5-({4-[3-
(methylsulfanyl)anilino|piperidin-1-vl}sulfonyl)thien-2-
yl]methyl}benzamide;
          4-chloro-N-({5-[(4-{3-nitroanilino}piperidin-1-
vl)sulfonvl]thien-2-vl}methvl)benzamide;
```

```
Appln. No. 10/070,954
Amdt. dated March 3, 2010
Reply to Office Action of November 3, 2009
```

```
4-chloro-N-[(5-{[4-(2-methoxvanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          3-({1-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2-
yl) sulfonyl] piperidin-4-yl amino) benzamide;
          4-chloro-N-({5-[(4-{2-nitro-4-
[(trifluoromethyl)sulfonyl]anilino}piperidin-1-
yl) sulfonyl] thien-2-yl}methyl) benzamide;
          4-chloro-N-[(5-{[4-(4-chloroanilino)piperidin-1-
vl]sulfonvl}thien-2-vl)methvl]benzamide;
          4-chloro-N-({5-[(4-{4-
[(trifluoromethyl)sulfonyl]anilino}piperidin-1-
yl) sulfonyl] thien-2-yl }methyl) benzamide;
          4-chloro-N-({5-[(4-{2-nitroanilino}piperidin-1-
vl)sulfonvl]thien-2-vl}methvl)benzamide:
          N-{ [5-({4-[4-(aminocarbonyl)anilino]piperidin-1-
yl}sulfonyl)thien-2-yl]methyl}-4-chlorobenzamide;
          N-[(5-{[4-(3-chloroanilino)piperidin-1-
vl]sulfonvl}thien-2-vl)methvl]-3-nitrobenzamide;
          4-chloro-N-[(5-{[4-(3-chloroanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          4-chloro-N-[(5-{[4-(3-methoxyanilino)piperidin-1-
vl]sulfonvl}thien-2-vl)methvl]benzamide;
```

```
Appln. No. 10/070,954
Amdt. dated March 3, 2010
Reply to Office Action of November 3, 2009
```

```
4-chloro-N-{[5-({4-[3-
(methylsulfonyl) anilino] piperidin-1-yl}sulfonyl) thien-2-
yl]methyl}benzamide;
          N-[(5-{[4-(2-aminoanilino)piperidin-1-
v1]sulfonv1}thien-2-v1)methv11-4-chlorobenzamide;
          4-chloro-N-[(5-{[4-(2-hydroxyanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          4-chloro-N-[(5-{[4-(4-hydroxyanilino)piperidin-1-
yl]sulfonyl}thien-2-vl)methvl]benzamide;
          4-chloro-N-[(5-{[4-(3-toluidino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          N-[(5-{[4-(3-tert-butylanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;
          4-chloro-N-[(5-{[4-(2-propvlanilino)piperidin-1-
vl|sulfonvl}thien-2-vl)methvl|benzamide:
          4-chloro-N-{[5-({4-[(2,2-dioxido-1,3-dihydro-2-
benzothien-5-yl)amino|piperidin-1-yl}sulfonyl)thien-2-
vl]methvl}benzamide;
          4-chloro-N-[(5-{[4-(2,3-dihvdro-1H-inden-5-
ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;
          4-chloro-N-[(5-{[4-(4-propylanilino)piperidin-1-
vl|sulfonyl}thien-2-vl)methvl|benzamide;
          4-chloro-N-[(5-{[4-({3-nitropyridin-2-
yl amino) piperidin-1-yl] sulfonyl thien-2-yl) methyl] benzamide;
```

```
Appln. No. 10/070,954
Amdt. dated March 3, 2010
Reply to Office Action of November 3, 2009
```

```
N-{ [5-({4-[(3-aminopyridin-2-yl)amino]piperidin-1-
yl}sulfonyl)thien-2-yl]methyl}-4-chlorobenzamide;
          4-chloro-N-[(5-{[4-(pyrimidin-2-ylamino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          4-chloro-N-({5-[(4-{[4-(trifluoromethyl)pyrimidin-2-
yl]amino}piperidin-1-yl)sulfonyl]thien-2-yl}methyl)benzamide;
          4-chloro-N-[(5-{[4-(3-ethylanilino)piperidin-1-
vllsulfonvl}thien-2-vl)methvllbenzamide;
          4-chloro-N-[(5-{[4-(5,6,7,8-tetrahydronaphthalen-1-
ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;
          4-chloro-N-[(5-{[4-(quinolin-5-ylamino)piperidin-1-
vl]sulfonvl}thien-2-vl)methvl]benzamide;
          4-chloro-N-[(5-{[4-(quinolin-8-ylamino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          4-nitro-N-({5-[(4-{3-
[(trifluoromethyl)sulfonyl]anilino}piperidin-1-
yl)sulfonyl]thien-2-yl}methyl)benzamide;
          N-[(5-{[4-(1H-1,2,3-benzotriazol-1-v1)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;
          N-[(5-\{[4-(2,4-difluorobenzoyl)piperidin-1-
vl]sulfonvl}thien-2-vl)methvl]-4-nitrobenzamide;
          N-[(5-{[4-(1H-1,2,3-benzotriazol-1-v1)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-4-nitrobenzamide;
```

```
Appln. No. 10/070,954
Amdt. dated March 3, 2010
Reply to Office Action of November 3, 2009
```

```
3-nitro-N-[(5-{[4-(3-methoxyanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          N-{[5-({4-[3-(dimethylamino)anilino]piperidin-1-
v1\sulfonv1) thien-2-v1\methv1\-3-nitrobenzamide;
          3-nitro-N-{[5-({4-[3-
(methylsulfonyl) anilino|piperidin-1-yl}sulfonyl) thien-2-
yl]methyl}benzamide;
          3-nitro-N-{[5-({4-[3-
(methylsulfanyl)anilino|piperidin-1-vl}sulfonyl)thien-2-
yl]methyl}benzamide;
          N { [5 ({4 [3 (aminosulfonyl)anilino]piperidin 1
yl}sulfonyl)thien-2-yl]methyl}-3-nitrobenzamide;
          methyl 3-\{[1-(\{5-[(\{3-nitrobenzoyl\}amino)methyl]-
thien-2-yl}sulfonyl)-piperidin-4-yl]amino}benzoate;
          N-{ [5-({4-[3-(aminocarbonyl) anilino] piperidin-1-
v1\sulfonv1) thien-2-v1|methv1\-3-nitrobenzamide;
          3-nitro-N-({5-[(4-{3-nitroanilino}piperidin-1-
yl) sulfonyl] thien-2-yl}methyl) benzamide;
          3-nitro-N-[(5-{[4-(2-methoxyanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
               3-nitro-N-({5-[(4-{2-nitroanilino}piperidin-1-
yl) sulfonyl] thien-2-yl}methyl) benzamide;
          N-[(5-{[4-(4-chloroanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;
```

Appln. No. 10/070,954 Amdt. dated March 3, 2010 Reply to Office Action of November 3, 2009 3-nitro-N-({5-[(4-{4-[(trifluoromethyl)sulfonyl]anilino}piperidin-1yl) sulfonyl] thien-2-yl}methyl) benzamide; N-{[5-({4-[4-(aminocarbonyl)anilino]piperidin-1yl}sulfonyl)thien-2-yl]methyl}-3-nitrobenzamide; N-[(5-{[4-(3-propylanilino)piperidin-1yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide; N-[(5-{[4-(3-chloroanilino)piperidin-1yl]sulfonyl}thien-2-yl)methyl]-4-nitrobenzamide; 4-nitro-N-[(5-{[4-(3-methoxyanilino)piperidin-1vl]sulfonvl}thien-2-vl)methvl]benzamide; N-{ [5-({4-[3-(dimethylamino)anilino]piperidin-1yl}sulfonyl)thien-2-yl]methyl}-4-nitrobenzamide; 4-nitro-N-[(5-{[4-(3-propylanilino)piperidin-1vl]sulfonvl}thien-2-vl)methvl]benzamide; 4-nitro-N-{[5-({4-[3-(methylsulfonyl) anilino] piperidin-1-yl}sulfonyl) thien-2yl]methyl}benzamide; 4-nitro-N-{[5-({4-[3-(methylsulfanyl) anilino] piperidin-1-yl} sulfonyl) thien-2-

vllmethvl}benzamide:

N-{[5-({4-[3-(aminosulfonyl)anilino]piperidin-1yl}sulfonyl)thien 2 yl]methyl} 4 nitrobenzamide;

```
Appln. No. 10/070,954
Amdt. dated March 3, 2010
Reply to Office Action of November 3, 2009
```

```
methyl 3-\{[1-(\{5-[(\{4-nitrobenzoyl\}amino)methyl]-
thien-2-yl}sulfonyl)piperidin-4-yl]amino}benzoate;
          3-{[1-({5-[({4-nitrobenzovl}amino)methyl]thien-2-
yl}sulfonyl)piperidin-4-yl]amino}benzamide;
          4-nitro-N-({5-[(4-{3-nitroanilino}piperidin-1-
yl) sulfonyl] thien-2-yl}methyl) benzamide;
          4-nitro-N-[(5-{[4-(2-methoxyanilino)piperidin-1-
vl]sulfonvl}thien-2-vl)methvl]benzamide;
          4-nitro-N-({5-[(4-{2-nitroanilino}piperidin-1-
yl) sulfonyl] thien-2-yl}methyl) benzamide;
          N-[(5-{[4-(4-chloroanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-4-nitrobenzamide;
          4-nitro-N-({5-[(4-{4-
[(trifluoromethyl)sulfonyl]anilino}piperidin-1-
yl)sulfonyl]thien-2-yl}methyl)benzamide;
          N-{ [5-({4-[4-(aminocarbonyl)anilino]piperidin-1-
y1}sulfonyl)thien-2-y1]methyl}-4-nitrobenzamide;
          N-({5-[(4-anilinopiperidin-1-yl)sulfonyl]thien-2-
v1}methv1)-3-nitrobenzamide:
          N-({5-[(4-anilinopiperidin-1-yl)sulfonyl]thien-2-
y1}methyl)-4-nitrobenzamide;
          3-nitro-N-[(5-{[4-({3-nitropyridin-2-
yl amino) piperidin-1-yl] sulfonyl thien-2-yl) methyl] benzamide;
```

```
Appln. No. 10/070,954
Amdt. dated March 3, 2010
Reply to Office Action of November 3, 2009
```

```
N-{ [5-({4-[(2,2-dioxido-1,3-dihydro-2-benzothien-5-
vl)amino|piperidin-1-vl}sulfonvl)thien-2-vl|methvl}-3-
nitrobenzamide:
          N-[(5-{[4-(2,3-dihydro-1H-inden-5-ylamino)piperidin-
1-yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;
          3-nitro-N-[(5-{[4-(2-propylanilino)piperidin-1-
vl|sulfonvl}thien-2-vl)methvl|benzamide;
          3-nitro-N-[(5-{[4-(4-propylanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          N- [(5-{[4-(3-tert-butylanilino)piperidin-1-
vl]sulfonvl}thien-2-vl)methvl]-3-nitrobenzamide;
          3-nitro-N-[(5-{[4-(2-phenylethyl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          3-nitro-N-{[5-({4-[3-(morpholin-4-
vlsulfonvl)anilino|piperidin 1-vl}sulfonvl)thien-2-
yl]methyl}benzamide;
          4-nitro-N-[(5-{[4-(pyrimidin-2-ylamino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          N-{[5-({4-[(3-aminopyridin-2-yl)amino]piperidin-1-
v1\sulfonv1)thien-2-v1\methv1\-4-nitrobenzamide;
          4-nitro-N-[(5-{[4-({3-nitropyridin-2-
yl}amino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;
          N-[(5-{[4-(2,3-dihydro-1H-inden-5-ylamino)piperidin-
1-vllsulfonvl}thien-2-vl)methvll-4-nitrobenzamide;
```

```
Appln. No. 10/070,954
Amdt. dated March 3, 2010
Reply to Office Action of November 3, 2009
```

```
4-nitro-N-[(5-{[4-(2-propylanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          4-nitro-N-[(5-{[4-(4-propylanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          N-[(5-{[4-(3-tert-butvlanilino)piperidin-1-
vl]sulfonyl}thien-2-yl)methyl]-4-nitrobenzamide;
          4-nitro-N-[(5-{[4-(2-phenylethyl)piperidin-1-
vl|sulfonvl}thien-2-vl)methvl|benzamide;
          4-nitro-N-{[5-({4-[3-(morpholin-4-
ylsulfonyl)anilino|piperidin-1-yl}sulfonyl)thien-2-
yl]methyl}benzamide;
          N-[(5-{[4-(2-aminoanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;
          3-nitro-N-[(5-{[4-(pyrimidin-2-ylamino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          N-{[5-({4-[(3-aminopyridin-2-vl)amino]piperidin-1-
yl}sulfonyl)thien-2-yl]methyl}-3-nitrobenzamide;
          N-({5-[(4-{2-nitro-4-
[(trifluoromethyl)sulfonyl]anilino}piperidin-1-
v1) sulfony1] thien-2-y1 \methy1) -3-methoxybenzamide;
          N-[(5-{[4-(3-ethylanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;
          3-nitro-N-[(5-{[4-(5,6,7,8-tetrahydronaphthalen-1-
vlamino) piperidin-1-yl] sulfonyl }thien-2-yl) methyl] benzamide;
```

```
4-nitro-N-[(5-[4-(3-propylphenoxy)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          N-[(5-{[4-(2,4-difluorobenzoyl)piperidin-1-
vl]sulfonvl}thien-2-vl)methvl]-3-nitrobenzamide;
          N-[(5-{[4-(2,4-difluorobenzoyl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;
          2-Hydroxy-N-({5-[(4-{3-
[(trifluoromethyl)sulfonyl]anilino}piperidin-1-
vl)sulfonvl]thien-2-vl}methvl)benzamide;
          N-[(5-{[4-(1H-1,2,3-benzotriazol-1-vl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;
          N-[(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-
vl]sulfonvl}thien-2-vl)methvl]-2-hvdroxybenzamide;
          3-methoxy-N-[(5-{[4-(3-methoxyanilino)piperidin-1-
vllsulfonvl}thien-2-vl)methvllbenzamide;
          N-{[5-({4-[3-(dimethylamino)anilino]piperidin-1-
y1}sulfony1)thien-2-y1]methy1}-3-methoxybenzamide;
          3-methoxy-N-[(5-{[4-(3-propylanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          3-methoxy-N-{[5-({4-[3-
(methylsulfonyl)anilino|piperidin-1-yl}sulfonyl)thien-2-
vl]methvl}benzamide;
```

```
Appln. No. 10/070,954
Amdt. dated March 3, 2010
Reply to Office Action of November 3, 2009
```

```
3-methoxv-N-{[5-({4-[3-
(methylsulfanyl)anilino]piperidin-1-yl}sulfonyl)thien-2-
yl]methyl}benzamide;
          methyl 3-({1-[(5-{[(3-methoxybenzovl)amino]-
methyl}thien-2-yl)sulfonyl]piperidin-4-yl}amino)-benzoate;
          N-{ [5-({4-[3-(aminocarbonyl)anilino]piperidin-1-
yl}sulfonyl)thien-2-yl]methyl}-3-methoxybenzamide;
          3-methoxy-N-[(5-{[4-(2-methoxyanilino)piperidin-1-
yl]sulfonyl}thien-2-vl)methyl]benzamide:
          N-({5-[(4-{3-nitroanilino}piperidin-1-
yl)sulfonyl]thien-2-yl}methyl)-3-methoxybenzamide;
          N-({5-[(4-{2-nitroanilino}piperidin-1-
yl)sulfonyl]thien-2-vl}methvl)-3-methoxybenzamide;
          N-{[5-({4-[4-(aminocarbonyl)anilino]piperidin-1-
yl}sulfonyl)thien-2-yl]methyl}-3-methoxybenzamide;
          N-[(5-{[4-(3-chloroanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;
          N-[(5-{[4-(4-chloroanilino)piperidin-1-
vl]sulfonvl}thien-2-vl)methvl]-3-methoxybenzamide:
          3-methoxy-N-({5-[(4-{4-
[(trifluoromethyl)sulfonyl]anilino}piperidin-1-
vl)sulfonvl]thien-2-vl}methvl)benzamide:
          N-({5 [(4-{3-[amino(imino)methyl]anilino}piperidin-
1 yl)sulfonyl]thien-2-yl}methyl) 3-methoxybenzamide;
```

```
Appln. No. 10/070,954
Amdt. dated March 3, 2010
Reply to Office Action of November 3, 2009
               3-methoxy-N-({5-[(4-{3-
[(trifluoromethyl)sulfonyl]anilino}piperidin-1-
yl) sulfonyl] thien-2-yl \methyl) benzamide;
          N-({5-[(4-anilinopiperidin-1-yl)sulfonyl]thien-2-
yl}methyl)-3-methoxybenzamide;
          N-[(5-{[4-(4-hydroxyanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;
          N-[(5-{[4-(2-hydroxyanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;
          3-methoxy-N-[(5-{[4-(pyrimidin-2-vlamino)piperidin-
1-yl]sulfonyl}thien-2-yl)methyl]benzamide:
          N-{[5-({4-[(3-aminopyridin-2-yl)amino]piperidin-1-
yl}sulfonyl)thien-2-yl]methyl}-3-methoxybenzamide;
          N-[(5-{[4-({3-nitropyridin-2-yl}amino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;
          N-{ [5-({4-[(2,2-dioxido-1,3-dihydro-2-benzothien-5-
yl)amino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}-3-
```

 $\label{eq:N-lamino} $$N-[(5-\{[4-(2,3-dihydro-1H-inden-5-ylamino)piperidin-1-yl]sulfonyl}$ thien-2-yl) methyl]-3-methoxybenzamide;$ 

3-methoxy-N-[(5-{[4-(2-propylanilino)piperidin-1yl]sulfonyl}thien-2-yl)methyl]benzamide;

methoxybenzamide:

3-methoxy-N-[(5-{[4-(4-propylanilino)piperidin-1y1]sulfonyl}thien-2-yl)methyl]benzamide;

```
Appln. No. 10/070,954

Amdt. dated March 3, 2010

Reply to Office Action of November 3, 2009
```

```
N-[(5-{[4-(3-tert-butylanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;
          3 methoxy N { [5 ({4 [3 (morpholin 4-
vlsulfonvl)anilino|piperidin-1-vl}sulfonvl)thien-2-
yl]methyl}benzamide;
          3-methoxy-N-[(5-{[4-(2-phenylethyl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          N-[(5-{[4-(3-ethylanilino)piperidin-1-
vl|sulfonvl}thien-2-vl)methvl|-3-methoxybenzamide;
          3-methoxy-N-[(5-{[4-(5,6,7,8-tetrahydronaphthalen-1-
ylamino) piperidin-1-yl] sulfonyl }thien-2-yl) methyl] benzamide;
          N-[(5-{[4-(1H-1,2,3-benzotriazol-1-v1)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-2-oxo-1,2-dihydropyridine-3-
carboxamide:
          N-[(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-
v1]sulfonyl}thien-2-v1)methyl]-3,4-dihydroxybenzamide;
          N-[(5-{[4-(1H-1,2,3-benzotriazol-1-vl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]pyridine-2-carboxamide;
          N-[(5-{[4-(hexyloxy)piperidin-1-yl]sulfonyl}thien-2-
yl) methyl] -3-methoxybenzamide;
          N-({5-[(4-heptanoylpiperidin-1-yl)sulfonyl]thien-2-
v1}methv1)-3-methoxybenzamide:
          4-chloro-N-[(5-{[4-(3-propylanilino)piperidin-1-
yl]sulfonyl}-2-furyl)methyl]benzamide;
```

```
Appln. No. 10/070,954
Amdt. dated March 3, 2010
Reply to Office Action of November 3, 2009
          4-chloro-N-[(5-{[4-(3-chloroanilino)piperidin-1-
yl]sulfonyl}-2-furyl)methyl]benzamide;
          4-chloro-N-[(5-{[4-(3-methoxyanilino)piperidin-1-
vllsulfonvl}-2-furvl)methvllbenzamide:
          4-chloro-N-{[5-({4-[3-
(trifluoromethyl)anilino|piperidin-1-yl}sulfonyl)-2-
furyl|methyl|benzamide;
          4-chloro-N-{[5-({4-[3-
(dimethylamino) anilino] piperidin-1-yl} sulfonyl) -2-
furyl]methyl}benzamide;
          4-chloro-N-{[5-({4-[3-
(methylsulfonyl) anilino|piperidin-1-yl}sulfonyl) -2-
furyl] methyl }benzamide;
          4-chloro-N-{[5-({4-[3-
(methylsulfanyl) anilino|piperidin-1-yl}sulfonyl) -2-
furyl|methyl|benzamide;
          methyl 3-({1-[(5-{[(4-chlorobenzovl)amino]methyl}-2-
furyl) sulfonyl] piperidin-4-yl}amino) benzoate;
          3-({1-[(5-{[(4-chlorobenzoyl)amino]methyl}-2-
furyl)sulfonyl]piperidin-4-yl}amino)benzamide;
          4-chloro-N-({5-[(4-{3-nitroanilino}piperidin-1-
yl)sulfonyl]-2-furyl}methyl)benzamide;
          4-chloro-N-[(5-{[4-(2-methoxyanilino)piperidin-1-
vl]sulfonvl}-2-furyl)methyl]benzamide;
```

4-chloro-N-({5-[(4-{2-nitroanilino}piperidin-1-yl)sulfonyl]-2-furyl}methyl)benzamide;

4-chloro-N-[(5-{[4-(4-chloroanilino)piperidin-1-yl]sulfonyl}-2-furyl)methyl]benzamide;

4-chloro-N-({5-[(4-{4[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]-2-furyl}methyl)benzamide;

N-{[5-((4-[4-(aminocarbonyl)anilino]piperidin-1-yl)sulfonyl]-2-furyl}methyl}-4-chlorobenzamide;

4-chloro-N-({5-[(4-{3[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]-2-furyl}methyl)benzamide; and

N-({5-[(4-anilinopiperidin-1-yl)sulfonyl]-2-furyl}methyl)-4-chlorobenzamide;—and\_

12. (Previously Presented) A sulfonamide compound
according to claim 11, which is selected from the group
consisting of:

4-chloro-N-[(5-{[4-(2,4-difluorobenzoyl)piperidin-1y1]sulfonyl}thien-2-yl)methyl]benzamide;

 $N-(\{5-[\,(4-anilinopiperidin-1-y1)\,sulfonyl\,]\,thien-2-$ 

y1}methy1)-4-chlorobenzamide;

 $\label{eq:N-[(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;}$ 

N-[(5-{[4-(1H-benzimidazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;
4-chloro-N-{[5-({4-[3-propylanilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

 $\label{lem:convergence} $$4$-chloro-N-[(5-{[4-(4-chloroanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;$ 

 $\label{lem:decomposition} $$4-nitro-N-[(5-\{[4-(3-methoxyanilino)piperidin-1-yl]sulfonyl\}thien-2-yl)methyl]benzamide;$ 

nitrobenzoyl}amino)methyl]thien-2-yl}sulfonyl)piperidin-4yl]amino)benzoate;

 $N-[(5-\{[4-(1H-1,2,3-benzotriazol-1-yl])piperidin-1-yl]sulfonyl\}thien-2-yl)methyl]-2-hydroxybenzamide; and <math display="block">N-(\{5-[(4-\{2-nitroanilino\}piperidin-1-yl)sulfonyl]thien-2-yl\}methyl)-3-methoxybenzamide.$ 

### 13-19. (Cancelled)

20. (Previously Presented) A pharmaceutical composition containing at least one sulfonamide compound according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.

21. (Currently Amended) Process for the preparation of a sulfonamide compound according to claim 1, comprising reacting a sulfonyl chloride according to formula V

$$Ar^{1}_{O}H^{-}(CH_{2})_{n}Ar^{2}SO_{2}CI$$

with an amine according to formula VIII

whereby

n is an integer of from 0 to 5,
n' is an integer of from 0 to 4,

 $R_6 - \underline{R}^6$  is selected from the group consisting of hydrogen, substituted or unsubstituted  $C_1 - C_6$  alkyl, substituted or unsubstituted  $C_1 - C_6$  alkoxy, OH, halogen, nitro, cyano, sulfonyl and oxo;

 $L^1$  and  $L^2$  are independently selected from the group consisting of hydrogen, substituted or unsubstituted  $C_2$ - $C_6$  alkyl, substituted or unsubstituted  $C_2$ - $C_6$  alkenyl, and substituted or unsubstituted  $C_3$ - $C_6$  alkynyl; or  $L^1$  and  $L^2$  are independently selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted aryl, heteroaryl-  $C_1$ - $C_6$  alkyl, heteroaryl-  $C_1$ - $C_6$  alkyl, substituted or unsubstituted cyclic  $C_4$ - $C_6$  alkyl

optionally containing 1-3 heteroatoms and optionally fused with aryl or heteroaryl,  $-C(O)R^3$ ,  $-C(O)OR^3$ ,  $-C(O)-NR^3'R^3$ ,  $-NR^3'R^3$ ,  $-NR^3'C(O)R^3$ ,  $-NR^3'C(O)R^3$ ,  $-NR^3'C(O)R^3$ ,  $-NR^3'C(O)R^3$ ,  $-NR^3'C(O)R^3$ ,  $-NR^3'C(O)R^3$ ,  $-NR^3'R^3$ ,  $-NR^3C(O)R^3$ ,  $-NR^3$ ,  $-NR^3$ ,  $-NR^3$ , -N

with  $R^3$  and  $R^{3'}$  being substituents independently selected from the group consisting of hydrogen, substituted or unsubstituted  $C_1$ - $C_6$  alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aryl-  $C_1$ - $C_6$  alkyl and substituted or unsubstituted heteroaryl-  $C_1$ - $C_6$  alkyl;

said aryl or heteroaryl groups being optionally substituted  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl, amino, acylamino, aminocarbonyl,  $C_2$ - $C_6$  alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfonyl, sulfoxy and  $C_1$ - $C_6$  thioalkoxy.

- \$22.\$ (Previously Presented) A process according to claim 21, wherein said sulfonyl chloride of formula V is obtained by
  - a) coupling an amine of formula II:

$$R^1HN-(CH_2)$$
  $Ar^2$ 

with an acyl chloride of formula III:

to provide an amide of formula IV:

 $\label{eq:bound} \mbox{b) sulfonating the amide of formula IV to provide}$  the sulfonyl chloride of formula V

## 23-26. (Cancelled)

- 27. (Previously Presented) The sulfonamide compound according to claim 1 wherein n is an integer of from 1 to 3.
- 28. (Previously Presented) The sulfonamide compound according to claim 27 wherein n is 1.
- 29. (Previously Presented) The composition according to claim 2 wherein n is an integer of from 1 to 3.
- 30. (Previously Presented) The composition according to claim 29 wherein n is 1.

Appln. No. 10/070,954 Amdt. dated March 3, 2010

Reply to Office Action of November 3, 2009

31. (Currently Amended) The composition according to claim  $3-\underline{2}$  wherein n is 1 or 2.

## 32-34. (Cancelled)

35. (Previously Presented) The sulfonamide compound according to claim 5 wherein the  $C_1\text{-}C_6$  alkyl group is trihalomethyl.

# 36-41. (Cancelled)